Evidence map›Paper›PMID 39218980›Full record

ArticleExperimental & molecular medicine2024

Emerin mislocalization during chromatin bridge resolution can drive prostate cancer cell invasiveness in a collagen-rich microenvironment.

Marta Popęda, Kamil Kowalski, Tomasz Wenta, Galina V Beznoussenko, Michał Rychłowski, Alexander Mironov, Zeno Lavagnino, Sara Barozzi, Julia Richert, Rebecca Bertolio and 11 more

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Emerin expression stratification across breast cancer subtypes.Cancer treatment and research communications · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Marta Popęda *Division of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.ORCID http://orcid.org/0000-0002-4596-4837
Kamil Kowalski *Division of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.
Tomasz WentaDepartment of General and Medical Biochemistry, Faculty of Biology, University of Gdansk, Gdansk, Poland.
Galina V BeznoussenkoIFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-1876-4098
Michał RychłowskiLaboratory of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Alexander MironovIFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
Zeno LavagninoIFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.ORCID http://orcid.org/0000-0002-7247-8084
Sara BarozziIFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
Julia RichertDivision of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.
Rebecca BertolioInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Area Science Park-Padriciano, Trieste, Italy.
Kamil MyszczyńskiCentre of Biostatistics and Bioinformatics Analysis, Medical University of Gdansk, Gdansk, Poland.
Jolanta SzadeDepartment of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Michał BieńkowskiDepartment of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Kevin MiszewskiDepartment of Urology, Medical University of Gdańsk, Gdańsk, Poland.
Marcin MatuszewskiDepartment of Urology, Medical University of Gdańsk, Gdańsk, Poland.
Anna J ŻaczekDivision of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.ORCID http://orcid.org/0000-0003-1482-6068
Luca BragaInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Area Science Park-Padriciano, Trieste, Italy.ORCID http://orcid.org/0000-0002-9827-6755
Giannino Del SalIFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy.
Natalia Bednarz-KnollDivision of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland.
Paolo MaiuriDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.ORCID http://orcid.org/0000-0001-5079-445X
Paulina NastałyDivision of Translational Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdańsk, Poland. paulina.nastaly@gumed.edu.pl.ORCID http://orcid.org/0000-0003-4811-4915

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 22174Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 22759Narodowe Centrum Nauki (National Science Centre) 2017/26/D/NZ5/01088
6 · The paper itself

Abstract

Micronuclei (MN) can form through many mechanisms, including the breakage of aberrant cytokinetic chromatin bridges. The frequent observation of MN in tumors suggests that they might not merely be passive elements but could instead play active roles in tumor progression. Here, we propose a mechanism through which the presence of micronuclei could induce specific phenotypic and functional changes in cells and increase the invasive potential of cancer cells. Through the integration of diverse in vitro imaging and molecular techniques supported by clinical samples from patients with prostate cancer (PCa) defined as high-risk by the D'Amico classification, we demonstrate that the resolution of chromosome bridges can result in the accumulation of Emerin and the formation of Emerin-rich MN. These structures are negative for Lamin A/C and positive for the Lamin-B receptor and Sec61β. MN can act as a protein sinks and result in the pauperization of Emerin from the nuclear envelope. The Emerin mislocalization phenotype is associated with a molecular signature that is correlated with a poor prognosis in PCa patients and is enriched in metastatic samples. Emerin mislocalization corresponds with increases in the migratory and invasive potential of tumor cells, especially in a collagen-rich microenvironment. Our study demonstrates that the mislocalization of Emerin to MN results in increased cell invasiveness, thereby worsening patient prognosis.

Indexed as

ChromatinCollagenMembrane ProteinsNeoplasm InvasivenessNuclear ProteinsProstatic NeoplasmsTumor MicroenvironmentCell Line, TumorCell MovementHumansMaleMicronuclei, Chromosome-DefectiveNuclear EnvelopeChromatinCollagenemerinMembrane ProteinsNuclear Proteins

Identifiers

PMID39218980
PMCPMC11446916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.